• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile

Giuseppe

Emeritus
Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile
Geneva, Switzerland, 1?3 October 2007

Executive summary
Human infections with highly pathogenic avian influenza A (H5N1) viruses present a serious and highly complex public health challenge.

In May 1997, the first human case of H5N1 virus infection was identified and by the end of the same year a total of 18 cases had been confirmed.

In 2003 and 2004, H5N1 viruses re-emerged and spread rapidly among poultry in several Asian countries with associated human infections.

Since February 2003, millions of birds have been infected and more than 360 human cases recorded, with more than 230 deaths in 12 countries in
Africa, Asia and Europe.

Currently, H5N1 is an avian pathogen that has had a devastating agricultural and economic impact on the communities it has affected.

Although it causes infections relatively rarely in people, when they occur, such infections have been frequently fatal.

However, H5N1 viruses continue to evolve and could develop into a much greater public health threat if they acquire the ability to cause sustained and widespread human-to-human transmission.

Such a transformation could result in the next influenza pandemic.

Addressing H5N1 as an agricultural, zoonotic and potential pandemic threat has proved to be complex and problematic for public health and animal health agencies and authorities.

The development and potentially imminent availability of approved human vaccines against H5N1 marks an important milestone in global efforts to address this threat.

As with other influenza vaccines, the development of effective H5N1 vaccines is notable because vaccination is potentially the best form of protection by preventing or reducing the chance of severe illness or death in people exposed to the H5N1 virus.

This is true both in the current non-pandemic situation (in which some individuals or populations are at elevated risk of zoonotic infection with avian H5N1 viruses) and in the future should H5N1 viruses evolve into a human pathogen capable of causing a pandemic.
(...)
-
http://www.who.int/csr/resources/publications/WHO_HSE_EPR_GIP_2008_1d.pdf
-----
 
Back
Top Bottom